Want to see JP:4579 full AI Analyst Report?
Top Page
RaQualia Pharma Inc.
(4579)
Select Model
Select Model
Rating:58Neutral
Price Target:
¥532.00
▼(-47.33% Downside)
Action:Reiterated
Date:08/17/26
The score is driven primarily by improving financial performance (return to profitability, strong gross margins, and a solid balance sheet), partially offset by inconsistent historical cash-flow/earnings stability. Technicals are mildly constructive near-term but remain weak versus longer-term moving averages and show near-overbought conditions. Valuation is the main drag due to the extremely high P/E and lack of dividend yield support.
Positive Factors
Revenue Growth
Revenue growth of 20.6% indicates improved partnering, licensing or collaboration activity. Sustained top-line expansion would broaden the base for milestone and royalty income, although the pack does not identify product-level contributors.
Negative Factors
Volatile Profitability
Profitability has not normalized: losses occurred in 2023–2024, while TTM net margin was about 4% and below 2025 profitability. Such uneven earnings make durable planning harder and increase dependence on successful licensing milestones.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Revenue growth of 20.6% indicates improved partnering, licensing or collaboration activity. Sustained top-line expansion would broaden the base for milestone and royalty income, although the pack does not identify product-level contributors.
Read all positive factors
RaQualia Pharma Inc. (4579) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥14.68B
Dividend YieldN/A
Average Volume (3M)352.93K
Price to Earnings (P/E)64.2
Beta (1Y)1.02
Revenue Growth20.64%
EPS GrowthN/A
CountryJP
Employees85
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)8.95
Shares Outstanding26,031,412
10 Day Avg. Volume795,170
30 Day Avg. Volume352,926
Financial Highlights & Ratios
PEG Ratio-0.58
Price to Book (P/B)3.47
Price to Sales (P/S)6.01
P/FCF Ratio-56.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)48.4
Revenue Forecast (FY)¥4.59B
RaQualia Pharma Inc. Business Overview & Revenue Model
Company Description
RaQualia Pharma Inc., established in 2008 and based in Nagoya, Japan, is a pharmaceutical company dedicated to the global research and development of innovative drug compounds. Its human therapeutic pipeline features several key candidates. Tegopr...
How the Company Makes Money
RaQualia Pharma primarily makes money by creating or acquiring drug candidates and then partnering with larger pharmaceutical companies to develop and commercialize them. Under this model, revenue typically comes from (1) upfront payments received...
RaQualia Pharma Inc. Financial Statement Overview
Summary
Income Statement
64
Positive
Balance Sheet
76
Positive
Cash Flow
55
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.90B | 3.98B | 3.11B | 1.90B | 2.92B | 2.78B |
| Gross Profit | 3.10B | 3.27B | 2.48B | 1.66B | 2.69B | 2.46B |
| EBITDA | 846.90M | 985.17M | 188.27M | -111.80M | 1.00B | 1.02B |
| Net Income | 161.22M | 273.12M | -495.03M | -323.66M | 723.39M | 755.79M |
Balance Sheet | ||||||
| Total Assets | 11.01B | 10.51B | 9.66B | 6.93B | 6.26B | 5.23B |
| Cash, Cash Equivalents and Short-Term Investments | 4.70B | 3.24B | 3.34B | 3.76B | 3.93B | 2.66B |
| Total Debt | 2.69B | 2.90B | 3.45B | 432.02M | 222.34M | 39.07M |
| Total Liabilities | 3.18B | 3.62B | 4.08B | 809.83M | 760.67M | 446.19M |
| Stockholders Equity | 7.83B | 6.90B | 5.57B | 6.12B | 5.50B | 4.79B |
Cash Flow | ||||||
| Free Cash Flow | 458.80M | -423.98M | 84.24M | -940.80M | 1.45B | 260.61M |
| Operating Cash Flow | 499.45M | -356.63M | 180.94M | -718.60M | 1.48B | 366.03M |
| Investing Cash Flow | -115.43M | 124.32M | -3.67B | -135.37M | -47.65M | -279.25M |
| Financing Cash Flow | 807.34M | 380.26M | 2.98B | 793.45M | -29.56M | -16.44M |
RaQualia Pharma Inc. Technical Analysis
Positive
1010.00
Price Trends
494.26
Positive
591.21
Negative
762.06
Negative
Market Momentum
22.80
Negative
68.02
Neutral
50.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4579, the sentiment is Positive. The current price of 1010 is above the 20-day moving average (MA) of 522.00, above the 50-day MA of 494.26, and above the 200-day MA of 762.06, indicating a neutral trend. The MACD of 22.80 indicates Negative momentum. The RSI at 68.02 is Neutral, neither overbought nor oversold. The STOCH value of 50.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4579.
RaQualia Pharma Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | ¥102.62B | -12.92 | -15.58% | ― | 7.12% | -137.21% | |
58 Neutral | ¥14.68B | 64.25 | ― | ― | 20.64% | ― | |
56 Neutral | ¥118.45B | -73.14 | ― | ― | 1662.38% | 42.86% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
48 Neutral | ¥144.63B | -39.43 | -6.88% | ― | 0.62% | 27.66% | |
46 Neutral | ¥15.55B | -4.09 | -156.47% | ― | 35.28% | 90.12% | |
45 Neutral | ¥9.21B | -7.66 | -32.74% | ― | 74.24% | -7.78% |
* General Sector Average
JP:4579
RaQualia Pharma Inc.
575.00
26.00
4.74%
JP:4563
AnGes
39.00
-57.00
-59.38%
JP:4587
Peptidream
1,108.50
-415.00
-27.24%
JP:4565
Sosei Group
1,116.00
212.00
23.45%
JP:4571
NanoCarrier Co., Ltd.
103.00
-48.00
-31.79%
JP:4588
Oncolys BioPharma, Inc.
4,020.00
3,382.00
530.09%
RaQualia Pharma Inc. Corporate Events
RaQualia Pharma Narrows Sales, Widens Loss but Strengthens Equity in First-Half 2026
Aug 14, 2026
RaQualia Pharma reported net sales of ¥1.46 billion for the first half of 2026, down 5.2% year-on-year, and a deeper loss attributable to owners of the parent of ¥466 million, as operating profit remained negative. Despite the weaker ear...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.